Impact of Nonselective Beta-blocker on Acute Kidney Injury in Cirrhotic Patients With Esophageal Varices
Status:
Unknown status
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
We will include patients with EV and EVB. They will be randomized to EVL vs. NSBB for primary
prevention And EVL+long-term NSBB vs. EVL+short-term NSBB for secondary prevention. 150
patients will be included in a 3-year period. Primary end-points are formation/progression of
ascites, acute kidney injury and survival. The other outcomes such as bleeding, rebleeding,
infection and other risk factors will be also analyzed.